To include your compound in the COVID-19 Resource Center, submit it here.

Long-acting Factor VIIa: Phase II data

Novo Nordisk announced in its 1Q11 earnings that a double-blind, international, Phase II

Read the full 137 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE